Replicate Bioscience Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities

<p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><img src="https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/image_92706a9ee1.png" alt="PatSnap MCP servers used for the Replicate Bioscience BD opportunity scan"></a></p><p><strong>This Replicate Bioscience Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows.</strong> Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP tests for recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. <a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener">Explore the MCP servers used in this report.</a></p><p><em>Decision date: 22 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply a usable record and must not be read as evidence of absence.</em></p><h2>Executive BD thesis</h2><p>Replicate Bioscience is screened as a potential partnering counterparty across asset licensing, regional commercialization, co-development, platform access and evidence-generation structures. The organization pipeline call returned 11 records at the decision date. The lead returned asset is <strong>RBI-4000</strong>, associated with Rabies virus protein and Rabies, at Phase 1. The immediate objective is to identify a narrow, executable right set and the evidence package required to test strategic fit.</p><p>A high-quality first meeting should confirm the current development owner, decision rights, territory availability, stage definitions, program status, patent ownership, third-party licenses, CMC readiness, clinical evidence, regulatory history and management’s preferred transaction structure. Pipeline size is a starting signal, not a substitute for strategic fit or diligence.</p><h2>Partnering shortlist</h2><table><thead><tr><th>Priority</th><th>Asset / workstream</th><th>Owner</th><th>Stage</th><th>Evidence package</th><th>IP risk screen</th><th>Deal precedent</th><th>Outreach rationale</th></tr></thead><tbody><tr><td>1</td><td><strong>RBI-4000</strong></td><td>Replicate Bioscience, Inc.</td><td>Phase 1</td><td>Pipeline record: Rabies virus protein; Rabies. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Replicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate's Self-Replicating RNA (srRNA) Rabies Vaccine in Latin America</td><td>Phase 1 asset with Rabies virus protein exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>2</td><td><strong>RBI-1000</strong></td><td>Replicate Bioscience, Inc.</td><td>Preclinical</td><td>Pipeline record: target not returned; Estrogen receptor positive breast cancer. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock Self-Replicating RNA Therapies for Obesity and Diabetes</td><td>Preclinical asset with target not returned exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>3</td><td><strong>RBI-5000</strong></td><td>Replicate Bioscience, Inc.</td><td>Preclinical</td><td>Pipeline record: target not returned; Infectious Mononucleosis. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Replicate Bioscience and Immunomic Therapeutics Form Collaboration to Combat Infectious Diseases and Cancers</td><td>Preclinical asset with target not returned exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>4</td><td><strong>RBI-6000</strong></td><td>Replicate Bioscience, Inc.</td><td>Preclinical</td><td>Pipeline record: target not returned; Respiratory Syncytial Virus Infections, Human Metapneumovirus Infection, Parainfluenzae virus infection. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Replicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate's Self-Replicating RNA (srRNA) Rabies Vaccine in Latin America</td><td>Preclinical asset with target not returned exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>5</td><td><strong>RBI-8000</strong></td><td>Replicate Bioscience, Inc.</td><td>Preclinical</td><td>Pipeline record: IL-18 x IL1; Autoimmune Diseases, Inflammation, Chronic tophaceous gout. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock Self-Replicating RNA Therapies for Obesity and Diabetes</td><td>Preclinical asset with IL-18 x IL1 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr></tbody></table><p><strong>Shortlist interpretation.</strong> Priority one should receive the fastest outreach only after the returned owner and stage are reconfirmed. Lower-ranked rows preserve option value and may support a regional license, co-development collaboration, asset carve-out, structured option, research partnership or financing-linked agreement. Any mismatch among asset name, owner, indication and stage is itself a diligence signal that may reflect a transfer, dormant program, territory split or portfolio reprioritization.</p><p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><img src="https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/image_2ed6f2cf76.png" alt="PatSnap Life Sciences MCP workflow for Replicate Bioscience"></a></p><h2>Pipeline and evidence-package readout</h2><p>The organization pipeline fetch anchors asset identity, target, indication and development stage when those fields are returned. Reconcile them against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, subgroup results, safety narratives, manufacturing comparability, stability data, health-authority feedback and the sponsor’s integrated development plan.</p><p>Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across the company record, trial registries and regulatory sources. A stage label should be translated into a milestone map with dates, endpoints, decision gates and remaining cost. Where the MCP result is missing or ambiguous, do not fill the gap by assumption: make the refresh and reconciliation an explicit condition before valuation.</p><h2>Deal precedents and structure signals</h2><table><thead><tr><th>Date</th><th>Transaction</th><th>Status</th><th>Disclosed economics</th></tr></thead><tbody><tr><td>2025-12-04</td><td>Replicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate's Self-Replicating RNA (srRNA) Rabies Vaccine in Latin America</td><td>Active</td><td>Not disclosed</td></tr><tr><td>2025-08-28</td><td>Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock Self-Replicating RNA Therapies for Obesity and Diabetes</td><td>Active</td><td>Not disclosed</td></tr><tr><td>2020-06-24</td><td>Replicate Bioscience and Immunomic Therapeutics Form Collaboration to Combat Infectious Diseases and Cancers</td><td>Active</td><td>Not disclosed</td></tr></tbody></table><p>Transaction precedents guide structure rather than mechanically determine price. Normalize every comparison for stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones, sublicensing, governance, termination and change-of-control provisions. Undisclosed economics can still reveal counterparties, strategic intent and preferred transaction form. A missing search result should trigger a broader licensor/licensee and asset-level search before negotiation.</p><h2>Financial capacity and partnering pressure</h2><ul><li><strong>Dare Bioscience, Inc. - 2021 Annual report</strong>: Dare Bioscience, Inc. - 2021 Annual report Market Information Net cash provided by financing activities Net cash provided by financing activities during the years ended December 31, 2021 and December 31, 2020 was approximately $75.8 million and $25.1 million, respectively, consisting primarily of net proceeds from sales of our common stock under our ATM sales agreements and our equity line. License and Royalty Agreements We agreed to make royalty and milestone payments under the license and development agreements related to XACIATO, Ovaprene, and Sildenafil Cream, 3.6%, and under other agreements related to our other clinical and preclinical candidates. For further discussion of these potential payments, see Note 3 "Strategic Agreements—Strategic Agreements for Pipeline Development" to the accompanying consolidated financial statements for more information about our license agreements. O</li><li><strong>Arcus Biosciences, Inc. - 2021 Annual report</strong>: Arcus Biosciences, Inc. - 2021 Annual report Gilead Collaboration Net cash provided by operating activities for the year ended December 31, 2020 was $111.2 million as compared to a use of $73.5 million for the prior year. The net $184.7 increase in cash provided is primarily due to $265.6 million in cash received at the close of the Gilead Collaboration Agreement in July 2020. The overall increase in net cash provided is partially offset by the $38.1 million increase in our net loss to $122.9 million and changes in non-cash items, including $12.8 million of increased expense from stock-based compensation, and changes in our asset and liability balances due to the timing of payments to or from our vendors and collaborators. Cash Provided by (Used in) Investing Activities Cash used in investing activities was $3.9 million for the year ended December 31, 2021 compared to $434.4 million cash</li><li><strong>PharmaCyte Biotech, Inc. - 2024 Annual report</strong>: PharmaCyte Biotech, Inc. - 2024 Annual report ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES. The cash and cash equivalents used in financing activities for the year ended April 30, 2024 was mainly attributable to the Repurchase Programs of approximately $28,198,000, redemption of preferred stock of approximately $16,161,000, and the cash provided by proceeds from the issuance of preferred stock of approximately $33,650,000, net of transaction costs. For the year ended April 30, 2023, the cash and cash equivalents used is mainly attributable to the Repurchase Programs of approximately $13,561,000. Critical Accounting Estimates Our Consolidated Financial Statements are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). We are required to make assumptions and estimates about future e</li></ul><p>Translate financial signals into BD questions. Confirm unrestricted cash, quarterly operating use, committed trials, debt and royalty financing, covenant constraints, near-term milestone receipts, commercial investment and management’s minimum runway threshold. A well-capitalized company may prefer a premium strategic collaboration; a constrained company may prioritize non-dilutive funding, regional monetization, cost sharing or a staged option.</p><h2>Current-awareness events and outreach triggers</h2><p>The Current Awareness <code>news_search</code> call did not return a parseable recent-event record at the decision date. Refresh the search before outreach and reconcile press releases, trial updates, regulatory events, financing announcements, management changes and partnering disclosures. Do not interpret the missing return as absence of news.</p><p>The best outreach window often follows a data readout, regulatory interaction, financing, portfolio review, leadership change or new transaction. Build a trigger calendar and identify the person who owns the asset, the therapeutic-area BD lead, the regional commercial lead and alliance-management stakeholders. Outreach should cite one verified event and one specific contribution the prospective partner can make.</p><h2>IP and freedom-to-operate risk screen</h2><p>The IP review is a gating workstream, not a footnote. Request the full patent-family schedule, inventorship and assignment history, prosecution status, expected expiries, patent-term adjustment or extension assumptions, opposition and litigation history, third-party licenses, field and territory restrictions, royalties, reach-through clauses, government rights and material-transfer obligations. Map composition-of-matter, method-of-use, formulation, manufacturing, biomarker, combination, platform and delivery claims to the exact rights proposed in the deal.</p><p>Screen risk as medium by default when an asset and owner are returned but the patent package has not been reviewed; elevate it to high where ownership, stage or program status is not returned. A license must match patents, know-how, data, regulatory references, materials, manufacturing rights and sublicensing rights to the precise field and geography. Complete a claim-level patent and FTO review before exclusivity, valuation or term-sheet approval.</p><h2>Recommended deal structures</h2><ul><li><strong>Regional license:</strong> useful when development or commercial capabilities differ by territory; define data access, regulatory responsibilities, supply, transfer pricing and reversion rights.</li><li><strong>Co-development:</strong> appropriate when both parties contribute clinical, biomarker, regulatory or commercial capabilities; specify cost sharing, governance, global strategy and opt-out economics.</li><li><strong>Option-to-license:</strong> reduces uncertainty before a defined data event; specify option fee, exercise trigger, diligence standard, exclusivity period and pre-agreed economics.</li><li><strong>Research or platform collaboration:</strong> suitable when the value resides in discovery or delivery capability; define targets, ownership of foreground IP, publication, replacement rights and downstream options.</li><li><strong>Structured financing:</strong> may combine equity, milestone funding, royalties or territory monetization; test covenant, accounting, control and change-of-control implications.</li></ul><h2>Outreach rationale and first-contact plan</h2><ol><li><strong>Identify the decision owner.</strong> Map the asset team, corporate-development lead, therapeutic-area leadership, regional commercial lead and alliance-management stakeholders.</li><li><strong>Lead with one verifiable gap.</strong> Focus on territory, evidence, diagnostics, manufacturing, delivery, financing or combination strategy rather than a generic partnership request.</li><li><strong>Attach a concise evidence package.</strong> Include the returned stage, indication footprint, relevant transaction precedent, partner contribution, proposed work plan and decision gates.</li><li><strong>Offer a structure.</strong> Present one primary and one fallback structure with clear rights, funding, governance and diligence assumptions.</li><li><strong>Define the diligence sequence.</strong> Request data-room access, IP/FTO materials, CMC documents, safety data, regulatory correspondence, economics and encumbrances before exclusivity.</li></ol><h2>Decision memo</h2><p><strong>ADVANCE TARGETED OUTREACH, SUBJECT TO EVIDENCE REFRESH.</strong> Replicate Bioscience offers a credible screening case because the MCP workflow identifies either a returned pipeline opportunity or a concrete set of evidence gaps that can be tested rapidly. The first contact should be tailored to a named asset where available, quantify the partner’s contribution, acknowledge IP and execution risks and avoid using pipeline count as a proxy for value.</p><p><strong>Required next diligence:</strong> refresh all four MCP searches; fetch full deal records for economics and rights; reconcile the newest financial filing and public event disclosures; verify owner and license chain; obtain patent-family and FTO work; review CMC, safety and regulatory materials; and model risk-adjusted economics by indication, territory and transaction structure.</p><p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><img src="https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/image_dddd7a2c83.png" alt="Explore PatSnap MCP servers for Replicate Bioscience partnering intelligence"></a></p><p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><strong>Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.</strong></a></p><hr><p><strong>Data provenance:</strong> PatSnap Company & Deal Intelligence MCP (<code>organization_pipeline_fetch</code>, <code>drug_deal_search</code>, <code>financial_report_search</code>) and Current Awareness MCP (<code>news_search</code>); accessed 22 July 2026. Counts, ownership and statuses may change as records update.</p>